AIM Rule 17 and Schedule 2(g) Disclosure
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your DEBS notes
The Company provides the following update pursuant to AIM Rule 17 and Schedule 2(g) (v) of the AIM Rules.
John Goold, Independent Non-Executive Director of the Company, is an Independent Non-Executive Director of Oncimmune Holdings plc ("Oncimmune"), a life science services business. Oncimmune was placed into administration on 26 March 2025.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.